Details of the Drug Combination

General Information of Drug Combination (ID: DCRK2PZ)

Drug Combination Name
Formoterol QMF149
Indication
Disease Entry Status REF
Asthma Approved [1]
Component Drugs Formoterol   DMSOURV QMF149   DMTY70Q
Small molecular drug N.A.

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Formoterol
Disease Entry ICD 11 Status REF
Allergic asthma CA23.0 Approved [2]
Asthma CA23 Approved [3]
Intrinsic asthma N.A. Approved [2]
Pulmonary emphysema CA21.Z Approved [2]
Formoterol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adrenergic receptor beta-2 (ADRB2) TT2CJVK ADRB2_HUMAN Agonist [5]
------------------------------------------------------------------------------------
Formoterol Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [6]
------------------------------------------------------------------------------------
Formoterol Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [7]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [8]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Formoterol Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Interleukin-5 (IL5) OTAFPSCO IL5_HUMAN Increases ADR [9]
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Increases ADR [9]
C-X-C motif chemokine 10 (CXCL10) OTTLQ6S0 CXL10_HUMAN Increases ADR [9]
------------------------------------------------------------------------------------
Indication(s) of QMF149
Disease Entry ICD 11 Status REF
Chronic obstructive pulmonary disease CA22 Phase 3 [4]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Asthma DC4RXC2 N. A. Approved [10]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02045875) Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence. U.S. National Institutes of Health.
2 Formoterol FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3465).
4 ClinicalTrials.gov (NCT02554786) A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma.
5 Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
6 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
7 A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
8 FDA Label of Formoterol. The 2020 official website of the U.S. Food and Drug Administration.
9 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
10 UniProt: the universal protein knowledgebase. Nucleic Acids Res. 2017 Jan 4;45(D1):D158-D169. (ID: O95477)